



truscreen
a world without
cervical cancer

NZX/ASX Announcement

12 October 2023

Strong Sales Growth in China in Improved Half Year Results

Highlights

- **Half year revenues up 33% on prior year to \$986,051 (FY2023: \$740,034)**
- **SUS unit sales up 28% on prior year to 95,040**
- **China continuing to be major contributor**
- **Zimbabwe tender underway, for 10,800 SUS in October 2023 to give strong start to Q3 FY2024**

Truscreen Group Limited (NZX/ASX:TRU) is pleased to report a 33% growth in H1 FY24 product sales and a 28% growth in sales of Single Use Disposable Sensors (SUS) sales against the same period last year.

China continues to grow strongly as we see a return to pre COVID levels, supported by the recent TruScreen recognition in major national Guidelines, by the *Chinese Society of Colposcopy and Cervical Pathology (CSCCP)*, published in the July edition of CSCCP's journal and the recommendation in the prestigious *Blue Book in China*.

Saudi Arabia has commenced commercial operations in Q2 FY24 and TruScreen is expecting a positive result from the national regulator in Mexico, Cofepris, in late FY24, which would enable TruScreen ® Ultra distribution in the public hospital system and inclusion in government screening programs. In Vietnam, 4 more major screening hospitals are pending approval of TruScreen with strong local authorities support.

Zimbabwe, under the National Aids Council program have now screened a total of 14,000 women in Masvingo province. The program continues with a further TruScreen SUS tender underway. A decision is expected in October 2023, which if positive will see the next order of 10,800 SUS from Zimbabwe give a strong start to Q3 2024 sales.

The CEO, Dr Beata Edling commented:

"We are pleased to see strong growth in our first half year results. TruScreen's recognition in the two top national guidelines in China is providing our distributor Siweixiangtai Tech Co. Ltd (SWXT) with the accreditation to rapidly expand the China business.

We are working to build on our China base and success in Zimbabwe to strengthen our position in other focus countries such as Vietnam and Mexico where we have expended significant effort over a number of years".

This announcement has been approved by the Board.

Ends

For more information, visit www.truscreen.com or contact:

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Julia Maguire
Investor Relations
julia@thecapitalnetwork.com.au

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra[®], is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In financial year 2023 alone, over 140000* examinations have been performed with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer"[®].

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*

Glossary:

Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a special brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the cells. Then it is sent to a laboratory for a pathologist to examine under a microscope. <https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/pap-test>

LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix, onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can be done at the same time, such as the human papillomavirus (HPV) test <https://www.cancer.net/cancer-types/cervical-cancer/diagnosis>

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test may also be done on a sample of cells which a person can collect on their own. <https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention>

Sensitivity and specificity mathematically describe the accuracy of a test which reports the presence or absence of a condition. If individuals who have the condition are considered "positive" and those who don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives and specificity is a measure of how well a test can identify true negatives:

- **Sensitivity** (true positive rate) is the probability of a positive test result, [conditioned](#) on the individual truly being positive.
- **Specificity** (true negative rate) is the probability of a negative test result, conditioned on the individual truly being negative ([Sensitivity and specificity – Wikipedia](#)).

For more information about the cervical cancer and cervical cancer screening in New Zealand and Australia, please see useful links:

New Zealand: [National Cervical Screening Programme | National Screening Unit \(nsu.govt.nz\)](#)

Australia: [Cervical cancer | Causes, Symptoms & Treatments | Cancer Council](#)